Cipla Q1FY27 profit falls 39% despite record India sales
Cipla’s consolidated net profit fell 39.2% year on year to Rs 789.05 crore, while revenue rose 2.3% to Rs 7,119.28 crore. Its India business grew 12%, supported by chronic-therapy launches and the obesity-drug partnership with Eli Lilly.
What happened
Cipla’s Q1FY27 profit fell 39% to Rs 789 crore despite record India sales, which grew 12%. The drugmaker expanded chronic-therapy offerings with Nintedanib and
Key facts
- Q1FY27 consolidated net profit: Rs 789.05 crore, down 39.19% YoY
- Revenue from operations: Rs 7,119.28 crore, up 2.3% YoY
- EBITDA: Rs 1,192 crore versus Rs 1,778 crore
- EBITDA margin: 16.7% versus 25.6%
- India business revenue growth: 12% YoY
- Chronic portfolio mix: 60.4%
- North America quarterly revenue: $162 million
- Albuterol US MDI market share: 21%
Why this matters
The Eli Lilly obesity-drug partnership highlights Cipla’s ability to use alliances to access high-growth therapy areas, even as near-term earnings pressure may affect deal capacity.
What to watch
- Whether India revenue sustains growth near or above 12% in the next quarter.
- Gross-margin and EBITDA-margin movement, which will indicate whether the profit decline was temporary or structural.
- Sales contribution, launch pace, and regulatory/supply execution for the Eli Lilly obesity-drug partnership.
- Growth trends in non-India businesses and any currency, pricing, or US-market pressure.
- Management commentary on one-time items or a revised full-year profitability outlook.
- Prioritize supply readiness, sales-force deployment, and physician education around obesity and chronic-therapy launches.
- Use India business momentum to improve product mix rather than pursue broad price-led volume growth.
- Provide investors with clearer disclosure on the drivers of the 39% profit decline, including any one-offs, cost increases, or international-market drag.
- Tighten cost control in lower-growth businesses while protecting investment behind differentiated domestic launches.